Opposition to IP protection for COVID-19 vaccines, therapies, tests and other technologies may only prevent eradication and treatment of the disease.
Kevin E. Noonan
Advertisement
Kevin E. Noonan, PhD, [email protected], is partner at McDonnell Boehnen Hulbert & Berghoff LLP and chair of the firm’s Biotechnology & Pharmaceuticals Practice Group.
Articles by Kevin E. Noonan
Advertisement
Latest Updated Articles
- Protecting Intellectual Property for COVID-19 Innovations
November 6th 2020
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
FDA Duloxetine Recall Highlights Generic Manufacturing Quality Gaps
2
Germany Pharma Tariff Threat: What Manufacturers Need to Know
3
PharmTech Weekly Roundup—June 19, 2026
4
Why the First Generic Single-Dose Flu Antiviral Approval Matters
5